About
Who We Are
Management Team
Scientific Advisors
Board of Directors
Pipeline & Research
Pipeline
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaborations
Expanded Access Policy
NEWS & MEDIA
Investors
Stock Overview
Events & Presentations
Financials & Filings
ESG
Corporate Governance
Careers
Contact Us
Select Page
Corporate Presentation
September 15, 2023
03.2025
Corporate Presentation
Download
Search for:
RECENT NEWS ARTICLES
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Files 2024 Annual Report on Form 10-K
BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
RECENT MEDIA COVERAGE
Seeking Alpha: BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
IO360: Developing a Molecule to Help Patients Respond to Immunotherapy
TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.
Ok
Privacy policy
